The role of soluble CD40L in autoimmune diseases

CD40−CD40L is essential for immune system modulation because it coordinates both adaptive and inflammatory responses.Systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, thrombocytopenic purpura, and rheumatoid arthritis are among the autoimmune illnesses in which it is espe...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Meryem, Mabrouk (author)
مؤلفون آخرون: Wahnou, Hicham (author), Merhi, Yahye (author), Abou-Saleh, Haissam (author), Guessous, Fadila (author), Zaid, Younes (author)
التنسيق: article
منشور في: 2025
الموضوعات:
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.jtauto.2025.100288
https://www.sciencedirect.com/science/article/pii/S2589909025000231
http://hdl.handle.net/10576/65521
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
الوصف
الملخص:CD40−CD40L is essential for immune system modulation because it coordinates both adaptive and inflammatory responses.Systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, thrombocytopenic purpura, and rheumatoid arthritis are among the autoimmune illnesses in which it is especially prominent. Thus, the CD40−CD40L axis is a significant therapeutic target, despite the fact that its inhibition was first constrained by thromboembolic adverse effects.New therapeutic approaches, such as nanotechnological methods and new-generation monoclonal antibodies, have been developed as a result of recent research with the goal of enhancing therapy efficacy and safety. This study opens up new avenues for the treatment of autoimmune illnesses by examining the pathophysiological consequences of CD40−CD40L and reviewing new treatments that target this pathway.